

INTRABIOTICS PHARMACEUTICALS INC /DE

Form 8-K

October 08, 2004

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 6, 2004**

**IntraBiotics Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b>	<b>0-29993</b>	<b>94-3200380</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**2483 East Bayshore Road, Suite 100  
Palo Alto, California 94303**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 526-6800**

**Not Applicable**

---

(Former name or former address, if changed since last report.)

---

**TABLE OF CONTENTS**

Item 8.01 Other Events.

Item 9.01 Financial Statements and Exhibits.

SIGNATURE

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 8.01 Other Events.**

On October 6, 2004, IntraBiotics Pharmaceuticals, Inc. (the *Company* ) issued a press release announcing that it had retained Lazard to advise the Company in evaluating strategic options.

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits.

99.1 Press release dated October 6, 2004.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**INTRABIOTICS PHARMACEUTICALS, INC.**

Date: October 7, 2004

/s/ David Tucker

---

David Tucker  
Principal Financial Officer

**Table of Contents**

EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release dated October 6, 2004.